Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: April 19, 2023
Reporting Period: First Quarter 2023
This filing announces the results of operations for the first quarter of 2023. The detailed financial data is contained in a press release furnished as Exhibit 99.1 and incorporated by reference.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the referenced Exhibit 99.1 (Press Release).
The company utilizes non-GAAP financial measures to assess performance, which exclude:
- Expenses associated with acquisitions, restructuring, and cost reduction initiatives.
- Costs related to a voluntary recall and certain regulatory costs.
- Tax benefits or expenses related to specified items and prior year tax position resolutions.
- Excess tax benefits from share-based compensation.
- Intangible amortization expense.
Material Changes
The filing text does not explicitly detail material changes versus the prior comparable period. It notes that the non-GAAP measures adjust for factors that are "unusual or unpredictable," implying such items impacted the reported period, but specific comparative data is absent from this summary document.
Guidance, Outlook, and Risks
Management Commentary: Management states that non-GAAP measures provide greater visibility on ongoing business performance and are used internally to monitor results. However, the company cautions investors to consider these measures in addition to, and not as a substitute for, GAAP financial measures.
Risks and Contingencies: The filing references specific unusual items affecting the period, including a voluntary recall and regulatory costs, though it does not elaborate on the specific nature or magnitude of these risks in the text provided.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2023 revenue, net earnings, and cash flow figures.
- Compare GAAP and non-GAAP results to understand the impact of the voluntary recall and restructuring costs.
- Verify the specific details of the "voluntary recall" mentioned as an adjustment item.
- Check for updated full-year guidance within the referenced press release.